BR112015005982A2 - di-hidropirrolidino-pirimidinas como inibidores de quinase - Google Patents

di-hidropirrolidino-pirimidinas como inibidores de quinase

Info

Publication number
BR112015005982A2
BR112015005982A2 BR112015005982A BR112015005982A BR112015005982A2 BR 112015005982 A2 BR112015005982 A2 BR 112015005982A2 BR 112015005982 A BR112015005982 A BR 112015005982A BR 112015005982 A BR112015005982 A BR 112015005982A BR 112015005982 A2 BR112015005982 A2 BR 112015005982A2
Authority
BR
Brazil
Prior art keywords
compounds
dihydropyrrolidine
pyrimidines
kinase inhibitors
therapeutic
Prior art date
Application number
BR112015005982A
Other languages
English (en)
Inventor
Shafer Cynthia
Poon Daniel
Tanner Huw
Patrick Dillon Michael
Lindvall Mika
Ramurthy Savithri
Subramanian Sharadha
Rauniyar Vivek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015005982A2 publication Critical patent/BR112015005982A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "di-hidropirrolidino-pirimidinas como inibidores de quinase". a presente invenção provê compostos de fórmula (i) e sais farmaceuticamente aceitáveis dos mesmos; (i) como ainda descritos no presente documento. a presente invenção ainda provê composições farmacêuticas que compreendem esses compostos, e combinações que compreendem esses compostos combinados com ou usados com um coagente terapêutico, assim como usos terapêuticos desses compostos e composições. são úteis no tratamento de doenças, tais como câncer que são associadas a ativação do erk1 e/ou erk2, e especialmente para cânceres dependentes de mapk, que mostram resistência a produtos terapêuticos mek inibidores de câncer.
BR112015005982A 2012-09-19 2013-09-17 di-hidropirrolidino-pirimidinas como inibidores de quinase BR112015005982A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112015005982A2 true BR112015005982A2 (pt) 2017-07-04

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005982A BR112015005982A2 (pt) 2012-09-19 2013-09-17 di-hidropirrolidino-pirimidinas como inibidores de quinase

Country Status (13)

Country Link
US (1) US9546173B2 (pt)
EP (1) EP2897961B1 (pt)
JP (1) JP6186440B2 (pt)
KR (1) KR20150056550A (pt)
CN (1) CN104640865B (pt)
AU (1) AU2013318283A1 (pt)
BR (1) BR112015005982A2 (pt)
CA (1) CA2882410A1 (pt)
EA (1) EA201590600A1 (pt)
ES (1) ES2612885T3 (pt)
IN (1) IN2015DN01328A (pt)
MX (1) MX2015003535A (pt)
WO (1) WO2014047020A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015003535A (es) * 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
CA3103711A1 (en) * 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
KR20220042184A (ko) * 2019-08-01 2022-04-04 프레테고 인코포레이티드 최종 당화 산물의 억제제
IL292349A (en) * 2019-12-10 2022-06-01 Hoffmann La Roche Novel braf inhibitors as paradox breakers
CR20220251A (es) 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona
WO2021218912A1 (zh) * 2020-04-30 2021-11-04 南京明德新药研发有限公司 含苯基并内磺酰胺的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4530852B2 (ja) * 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005068468A2 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
SI1838718T1 (sl) 2005-01-10 2011-08-31 Pfizer Pirolopirazoli, zmogljivi inhibitorji kinaze
DK1966151T3 (da) 2005-12-13 2012-01-30 Schering Corp Polycykliske indazolderivater, der er ERK-hæmmere
NZ581698A (en) 2007-06-05 2012-09-28 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
CN103298461A (zh) 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法
BR112013021896A2 (pt) 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
ES2620612T3 (es) * 2012-03-02 2017-06-29 Genentech, Inc. Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
MX2015003535A (es) * 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.

Also Published As

Publication number Publication date
EA201590600A1 (ru) 2015-07-30
ES2612885T3 (es) 2017-05-19
US9546173B2 (en) 2017-01-17
MX2015003535A (es) 2015-07-14
AU2013318283A1 (en) 2015-03-05
EP2897961A1 (en) 2015-07-29
CA2882410A1 (en) 2014-03-27
WO2014047020A1 (en) 2014-03-27
CN104640865A (zh) 2015-05-20
JP2015529248A (ja) 2015-10-05
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
IN2015DN01328A (pt) 2015-07-03
JP6186440B2 (ja) 2017-08-23
EP2897961B1 (en) 2016-10-26
CN104640865B (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
BR112015005982A2 (pt) di-hidropirrolidino-pirimidinas como inibidores de quinase
CY1120866T1 (el) Παρεμποδιστες dna-pk
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112015003859A2 (pt) compostos de pirazolopirimidina como inibidores de quinase
BR112014026801A2 (pt) 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazina-2-carbonitrila e usos terapêuticos do mesmo
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
BR112014022106A2 (pt) derivados macrocíclicos para o tratamento de doenças
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112012033253A2 (pt) novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112015022551A2 (pt) inibidores de amido pirrol
BR112013003864A2 (pt) compostos de pirrolpirimidina e usos dos mesmos
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112014016163A2 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)